Navigation Links
Enanta Announces Positive Phase 2 Results From Interferon-Free Combination Studies with ABT-450 for Hepatitis C Treatment to be Presented at EASL
Date:4/4/2012

WATERTOWN, Mass., April. 4, 2012 /PRNewswire/ --Enanta Pharmaceuticals, Inc., a research and development company dedicated to creating best-in-class small molecule drugs in the infectious disease field, announced today that key data from two of its hepatitis C (HCV) programs will be presented at the International Liver Congress™ 2012 (ILC2012), the annual meeting of the European Association for the Study of the Liver (EASL), April 18-22 in Barcelona, Spain.  Oral presentations will discuss Phase 2 results from "Pilot" and "Co-Pilot", which investigated two different interferon-free combination regimens containing ABT-450, the lead candidate from Enanta's collaborative HCV protease inhibitor program with Abbott.  ABT-450 will be included in two additional poster presentations and a third poster presentation will report in vitro data from Enanta's proprietary nucleotide HCV polymerase inhibitor program. Abstracts are available at www.easl.eu.  

Phase 2 Data Highlights

In the study known as "Co-Pilot," different doses of ABT-450/r, plus ABT-333 and ribavirin administered for 12 weeks showed sustained virological response at 12 weeks post treatment (SVR12) in 93 percent and 95 percent of treatment-naive genotype 1 (GT1) patients.  In these patients, response was independent of HCV subtype, host IL28B genotype or dose of ABT-450/r.  In addition, SVR12 was achieved in 47 percent of patients who were previous non-responders to past HCV treatment.

In a separate study, known as "Pilot", 91 percent of genotype 1 infected, treatment-naive patients taking ABT-450/r and ABT-072 combined with ribavirin administered for 12 weeks, achieved sustained viral response at 24 weeks (SVR24).

"The results from Pilot and Co-Pilot showed very encouraging levels of sustained response and suggest that ABT-450 could be an important component in new
'/>"/>

SOURCE Enanta Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Enanta Reports New Macrolide-Related Drug Class, Bicyclolides, to Combat Hospital and Community Acquired Superbug Infections, Including MRSA
2. Enanta Initiates Phase 1 Study on EDP-322, an Oral Antibiotic With Activity Against Hospital- and Community-Acquired MRSA
3. Abbott and Enanta Initiate Phase 1 Clinical Trial on ABT-450 HCV Protease Inhibitor
4. Abbott and Enanta Present Positive Initial Results from Phase 2 Study of ABT-450/r for Treatment of Hepatitis C
5. Enanta Enters Into Strategic Collaboration to Advance NS5A Inhibitor Candidate for HCV
6. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
7. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
8. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
9. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
10. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
11. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... PITTSBURGH , July 30, 2014   ... Markets Groups Inc.: OTC Pink: UPZS), a Delaware ... a distribution agreement with Larasan Pharmaceutical Corporation ("Larasan"), a ... products.  According to the agreement, US-based Larasan will ... gourmet 6" frozen pizza through Larasan,s vast distribution ...
(Date:7/30/2014)... Germany , July 30, 2014  invendo medical ... computer-assisted ("robotic") colonoscopy system, today announced the appointment of ... device executive, as a new member of its supervisory ... respected global visionary in the medical device industry. In ... Chief Executive Officer at Given Imaging Ltd. (NASDAQ/TASE: GIVN), ...
(Date:7/30/2014)... PARIS , July 30, 2014  Regeneron ... (EURONEXT: SAN and NYSE: SNY ) today ... alirocumab in people with hypercholesterolemia met their primary efficacy ... low-density lipoprotein cholesterol (LDL-C) at 24 weeks compared to ... antibody targeting PCSK9 (proprotein convertase subtilisin/kexin type 9). ...
Breaking Medicine Technology:Unique Pizza and Subs Announces Asian Distribution Agreement with Larasan Pharmaceutical Corporation 2Unique Pizza and Subs Announces Asian Distribution Agreement with Larasan Pharmaceutical Corporation 3invendo medical Appoints Nachum (Homi) Shamir To The Company's Board Of Directors 2invendo medical Appoints Nachum (Homi) Shamir To The Company's Board Of Directors 3Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 2Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 3Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 4Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 5Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 6Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 7Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 8
... LIUZHOU CITY, China , July 19 ... CNBI), ("China BCT" or the,"Company"), a leading pharmaceutical distributor, ... Province , China , today,announced that on ... Public,Accountants, A Professional Corporation, Glendale, California ("PKF,California"), ...
... 19 "This is a historic day for HIV prevention research. ... gel can help to prevent sexual transmission of HIV infection," said AVAC ... landmark microbicide trial presented today at the International AIDS Conference in ... "We believe ...
Cached Medicine Technology:China BCT Announces Auditor Change Within PKF Network 2China BCT Announces Auditor Change Within PKF Network 3AVAC Praises CAPRISA 004 Trial Collaborators and Participants for Historic Study - Trial Confirms Promise of ARV-Based Microbicides 2AVAC Praises CAPRISA 004 Trial Collaborators and Participants for Historic Study - Trial Confirms Promise of ARV-Based Microbicides 3AVAC Praises CAPRISA 004 Trial Collaborators and Participants for Historic Study - Trial Confirms Promise of ARV-Based Microbicides 4
(Date:7/30/2014)... Daily Gossip indicates in its 60 Second Panic ... attack is a feeling of intense stress and fear, which ... of symptoms that sufferers commonly deal with when panic attacks ... or anxiety. Naturally, panic attacks deeply affect lifestyle; this is ... them. , The 60 Second Panic Solution review promises to ...
(Date:7/30/2014)... July 30, 2014 The Restore My Blood ... from high blood sugar levels can now find an amazingly ... The new program was created by D. Chao and Andrew ... beneficial for patients when it comes to normalizing blood sugar ... there is a secret to the cure of diabetes that ...
(Date:7/30/2014)... weeks freshman will begin to pour onto college campuses, each student ... time of growth and the start to something big. Statistically speaking, ... as easy as it looks. Some sources cite as ... once and many will switch two or three times. Each switch ... switching in the later years of college. According to the ...
(Date:7/30/2014)... 30, 2014 Ticket Down is ... Munich vs. Chivas Guadalajara friendly exhibition match at the ... Cup, the one team that was left standing as the ... it through the world’s largest football competition and even embarrassed ... way to the cup. Germany was led by seven players ...
(Date:7/30/2014)... HealthDay Reporter WEDNESDAY, July 30, ... likely to develop dementia, but researchers have been unable to ... Specifically, they haven,t been able to figure out the ... bring on dementia, or does dementia cause people to become ... the journal Neurology sheds more light on the ...
Breaking Medicine News(10 mins):Health News:60 Second Panic Solution Review Reveals Unique Way to Stop Panic Attacks 2Health News:Restore My Blood Sugar Review Reveals Exclusive Ways to Normalize Blood Sugar 2Health News:Advice to College Freshman from Author Garrett Miller 2Health News:Advice to College Freshman from Author Garrett Miller 3Health News:Bayern Munich vs. Chivas Guadalajara Tickets Red Bull Arena: Ticket Down Slashes Ticket Prices for Chivas Guadalajara vs. Bayern Munich in Harrison, NJ 2Health News:Bayern Munich vs. Chivas Guadalajara Tickets Red Bull Arena: Ticket Down Slashes Ticket Prices for Chivas Guadalajara vs. Bayern Munich in Harrison, NJ 3Health News:Scientists Shed Light on Link Between Depression, Dementia 2Health News:Scientists Shed Light on Link Between Depression, Dementia 3
... OMCL ), a leading provider of system solutions to acute healthcare,facilities, will ... 2008 financial results., What: Omnicell second quarter ... 21, 2008, 1:30 p.m. PDT Who: Randall ... Rob Seim, chief financial officer Where: ...
... developing brain,s ability to make neural connections , , THURSDAY, ... affect brain development may be shared by the many ... new report shows. , The findings, published in the ... large sections missing on chromosomes in autistic people that ...
... Care Education and Updates for Kidney Dialysis Benefit, ... the,passage of the Medicare bill (H.R. 6331) yesterday, ... advocates, dialysis professionals, care,providers and manufacturers working together ... disease and kidney failure -- applauded the United,States ...
... The following is a,statement by Mark J. Feldman, ... that 70 percent of the U.S. population now ... encouraging news from the Centers for Disease,Control and ... Americans,receiving optimally fluoridated water. We know from years ...
... Healthcare and Educate Patients, SAN FRANCISCO ... Inc. and,Iverson Genetic Diagnostics, Inc. today announced ... reports for individuals receiving,Iverson,s molecular-based assay for ... DNA Direct will provide a customized,web-enabled tool ...
... the United States, List of ... Fur-Free Retailers and Designers to 100, SALT LAKE CITY, ... giant Overstock.com, Inc. (Nasdaq: OSTK ),and The Humane Society ... online that contain animal fur effective today. With,annual revenues exceeding ...
Cached Medicine News:Health News:Omnicell to Release Second Quarter 2008 Earnings Results on July 21 2Health News:Common Mechanisms May Contribute to Autism's Mutations 2Health News:Kidney Community Applauds Senate for Passage of End Stage Renal Disease (ESRD) Improvements 2Health News:DNA Direct and Iverson Genetics Announce Partnership to Provide Personalized Patient Reports for Warfarin Dosing Test Results 2Health News:DNA Direct and Iverson Genetics Announce Partnership to Provide Personalized Patient Reports for Warfarin Dosing Test Results 3Health News:Overstock.com Goes Fur Free 2Health News:Overstock.com Goes Fur Free 3
InterVascular HemaCarotid Patch product line offers the vascular surgeon a complete range of knitted, collagen coated patches in a wide range of sizes for carotid endarterectomy and angioplasty witho...
The VasoSeal Low Profile device is designed for smaller sheath angiography procedures. VasoSeal Low Profile. Seal your arterial punctures with confidence....
The VasoSeal Low Profile device is designed for smaller sheath angiography procedures. VasoSeal Low Profile. Seal your arterial punctures with confidence....
D-Stat Radial is a dry version of the D-Stat together with a compression band, and is designed for the control of surface bleeding from vascular access sites, including the sites on the radial artery...
Medicine Products: